TLXTelix Pharmaceuticals Limited
What is the market doing?
No clear lean: nothing decisive, though insiders net buying.
Rangebound, no clear trend. Oversold (RSI 29). Price is −7% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 22, 2026.
A token position, settled Sep 30, 2026, a few days of normal trading to cover. Up 21% since the previous count, up from 0.0% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How TLX is trading
Telix Pharmaceuticals Limited is −16% over the past year while the S&P 500 is +16%: 32 points behind the market. Through the fall, its own insiders bought $1.0M more stock than they sold.
1-year return · S&P 500 +16%
- vs 200-day average
- −6.8%
vs 200-day average · below trend, but not far
- RSI (14)
- 29
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 29%
Below its 52-week high
Details›
- Last close2026-10-23
- $9.14
- 1 monthS&P 500 −0.94%
- −19%
- 1 yearS&P 500 +16%
- −16%
- vs 50-day average$11.36
- −20%
- 52-week high
- $12.84
- 52-week low
- $6.41
- Annualised volatility
- 57%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-22
- $1.0M
| Year | Return |
|---|---|
| 2026 (year to date) | +22% |
| 2025 | −51% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Biotechnology
The closest names by size in the same industry